First Manhattan CO. LLC. Has $2.30 Million Stock Holdings in DiaMedica Therapeutics, Inc. $DMAC

Key Points

• First Manhattan Co. LLC reduced its stake in DiaMedica Therapeutics by 27.7%, selling 232,646 shares to hold a total of 606,435 shares valued at approximately $2.3 million.
• Several analysts have upgraded their price targets for DiaMedica Therapeutics, with estimates rising to between $11.00 and $14.00, while the stock holds a consensus rating of "Buy".
• Major shareholder Jan Stahlberg acquired over 1.5 million shares at $3.50 each, increasing their ownership by 29.55% and bringing their total holdings to around $23.7 million.

First Manhattan CO. LLC. lowered its stake in shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Free Report) by 27.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 606,435 shares of the company's stock after selling 232,646 shares during the quarter. First Manhattan CO. LLC. owned about 1.42% of DiaMedica Therapeutics worth $2,298,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Balyasny Asset Management L.P. acquired a new stake in DiaMedica Therapeutics during the fourth quarter worth approximately $79,000. Raymond James Financial Inc. acquired a new stake in DiaMedica Therapeutics during the fourth quarter worth approximately $83,000. Cornerstone Wealth Management LLC acquired a new stake in DiaMedica Therapeutics during the first quarter worth approximately $62,000. Dimensional Fund Advisors LP grew its position in DiaMedica Therapeutics by 14.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 19,339 shares of the company's stock worth $105,000 after buying an additional 2,380 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of DiaMedica Therapeutics in the 4th quarter valued at $122,000. Institutional investors and hedge funds own 10.12% of the company's stock.

Insider Buying and Selling at DiaMedica Therapeutics

In other DiaMedica Therapeutics news, major shareholder Jan Stahlberg acquired 1,542,857 shares of the stock in a transaction dated Wednesday, July 23rd. The stock was purchased at an average cost of $3.50 per share, with a total value of $5,399,999.50. Following the transaction, the insider owned 6,764,465 shares in the company, valued at approximately $23,675,627.50. The trade was a 29.55% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Over the last three months, insiders bought 2,542,857 shares of company stock valued at $11,358,598. Company insiders own 7.30% of the company's stock.

DiaMedica Therapeutics Trading Up 9.2%

NASDAQ:DMAC traded up $0.57 during trading hours on Monday, hitting $6.71. 1,152,489 shares of the company were exchanged, compared to its average volume of 196,256. The stock has a market capitalization of $346.58 million, a price-to-earnings ratio of -9.73 and a beta of 1.40. DiaMedica Therapeutics, Inc. has a one year low of $3.19 and a one year high of $7.49. The company has a fifty day simple moving average of $4.84 and a 200 day simple moving average of $4.52.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.18). Equities research analysts predict that DiaMedica Therapeutics, Inc. will post -0.59 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on DMAC. Craig Hallum lifted their price target on DiaMedica Therapeutics from $8.00 to $11.00 and gave the company a "buy" rating in a research note on Friday, July 18th. HC Wainwright reiterated a "buy" rating and issued a $12.00 price target on shares of DiaMedica Therapeutics in a research note on Friday, August 15th. Lake Street Capital lifted their price target on DiaMedica Therapeutics from $11.00 to $14.00 and gave the company a "buy" rating in a research note on Friday, July 18th. Finally, Wall Street Zen lowered DiaMedica Therapeutics from a "hold" rating to a "sell" rating in a research note on Tuesday, September 2nd. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $12.33.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.